BioSpace News Archive

Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that the company is working with third party groups and government agencies to reactivate the previously robust research and development to generate Ii-Key peptide vaccines against pandemic viruses

Fourth-quarter 2019 sales performance(3) driven by Dupixent® and Vaccines

Metagenics, Inc., a health sciences company, announced today the release of CardioLux HDL, the newest patent pending formula launched in the Metagenics product line.

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, announced it has retained the FreeMind Group, an international consulting firm dedicated to assisting life science organizations secure non-dilutive funding.

DisposeRx, Inc., manufacturer of the market leading at-home medication disposal solution, and Garden State Pharmacy Owners, the association of New Jersey independent pharmacies, have entered into a strategic partnership in which DisposeRx will be the preferred vendor.

Dyne Therapeutics, a biotechnology company pioneering targeted therapies for patients with serious muscle diseases, today announced the addition of three key members to its leadership team: Oxana Beskrovnaya, Ph.D., senior vice president and head of research; Chris Mix, M.D., senior vice president, clinical development; and John Najim, vice president, chemistry, manufacturing and controls (CMC).

BioVentrix, Inc., developer of the first transcatheter device for left ventricular remodeling after a heart attack, today announced it received renewal of the highest priority reimbursement in Germany for the Revivent TC™ TransCatheter Ventricular Enhancement System by achieving the NUB Status 1 designation from InEk, the German Institute for Hospital Remuneration.

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it has appointed Stephen Trowbridge to the role of Executive Vice President and Chief Financial Officer, effective February 5, 2020.

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cellular therapies for unmet medical needs, today provided an update from its ongoing Phase I/IIa clinical study of OpRegen®, the Company’s retinal pigment epithelium (RPE) transplant therapy, for the treatment of dry age-related macular degeneration (dry AMD)

International medical imaging IT and cybersecurity company Sectra (STO: SECT B) has signed a contract with Hillcrest Medical Center in Tulsa to add cardiology to their existing enterprise imaging solution.